m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG04346)
| Name |
TK-DLI
|
||||
|---|---|---|---|---|---|
| Synonyms |
TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara
Click to Show/Hide
|
||||
| Status |
Preregistration
|
||||
| TTD Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Thymidine kinase 1 (TK1)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||
Methyltransferase-like 14 (METTL14)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||